Skip to content

Owlyn MCP v0.1.0-alpha.3

Pre-release
Pre-release

Choose a tag to compare

@btitkin btitkin released this 09 Jul 17:00

Owlyn MCP v0.1.0-alpha.3

Owlyn MCP - Time-aware work sessions for AI agents.

This alpha focuses on Codex-first validation and hardening.

Highlights

  • Extended Codex MCP host validation completed on Windows.
  • All 8 Owlyn MCP tools remained visible and callable in Codex.
  • structuredContent worked in real Codex MCP host usage.
  • Core continuation behavior passed:
    • owlyn_should_continue returned should_continue: true
    • recommendation included:
      "Do not stop only because the current task is complete."
  • Safety gates passed:
    • approval gate
    • destructive action gate
    • high-risk gate
  • Mode behavior passed:
    • focused mode stops after current task
    • night_shift continues before deadline
    • marathon mode provides careful continuation guidance
  • Deadline-reached behavior passed.
  • Task ranking behavior passed.
  • Report/end flow passed.
  • Codex restart/reload behavior passed.
  • Persistent OWLYN_DB_PATH behavior passed.

Validation

Validated in:

  • Codex MCP host on Windows

Extended scenarios passed:

  • Tool visibility/status
  • Continue after first task
  • Approval gate
  • Destructive action gate
  • High-risk gate
  • Focused mode
  • Marathon mode
  • Deadline reached
  • Plan next ranking
  • Report/end
  • Restart/reload behavior
  • Persistent configured database path

Runtime changes

None.

This release does not change Owlyn MCP runtime behavior. It records and documents deeper Codex validation.

Known limitations

  • Codex MCP host on Windows is the primary validated host.
  • Cursor, Claude Desktop, and other MCP stdio hosts remain pending/future validation targets.
  • Owlyn does not keep an MCP host alive by itself.
  • The host agent must call Owlyn tools and follow the returned policy.
  • Clean database path validation is optional/future unless separately tested.
  • npm publishing is still not performed in this release.